Article

IDUA Mutational Profiling of a Cohort of 102 European Patients with Mucopolysaccharidosis Type I: Identification and Characterization of 35 Novel alpha-L-iduronidase (IDUA) Alleles

Consortium for Human Molecular Genetics, Milano Bicocca University, Monza, Italy.
Human Mutation (Impact Factor: 5.05). 06/2011; 32(6):E2189-210. DOI: 10.1002/humu.21479
Source: PubMed

ABSTRACT Mutational analysis of the IDUA gene was performed in a cohort of 102 European patients with mucopolysaccharidosis type I. A total of 54 distinct mutant IDUA alleles were identified, 34 of which were novel including 12 missense mutations, 2 nonsense mutations, 12 splicing mutations, 5 micro-deletions, 1 micro-duplication 1 translational initiation site mutation, and 1 'no-stop' change (p.X654RextX62). Evidence for the pathological significance of all novel mutations identified was sought by means of a range of methodological approaches, including the assessment of evolutionary conservation, RT-PCR/in vitro splicing analysis, MutPred analysis and visual inspection of the 3D-model of the IDUA protein. Taken together, these data not only demonstrate the remarkable mutational heterogeneity characterizing type 1 mucopolysaccharidosis but also illustrate our increasing ability to make deductions pertaining to the genotype-phenotype relationship in disorders manifesting a high degree of allelic heterogeneity.

Full-text

Available from: Camillo Rosano, May 23, 2015
0 Followers
 · 
139 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective Hurler syndrome is the most clinically severe form of an autosomal recessive lysosomal disorder characterized by the deficiency of α-L-iduronidase. The resulting accumulation of glycosaminoglycans causes progressive multisystem deterioration, resulting in death in childhood. Umbilical cord blood transplantation from unrelated donors has been previously shown to improve neurological outcomes of children younger than 2 years of age and prolong life. The purpose of this manuscript is to determine whether age at transplantation can predict cognitive outcomes.Methods Between June 1997 and February 2013, 31 patients with Hurler syndrome underwent umbilical cord blood transplantation and were evaluated at baseline and every 6 to 12 months thereafter. All 31 patients underwent complete neurodevelopmental evaluation (median follow-up 7.3 years, range 2–21.7) and a median of 7.0 evaluations (range 3–18).ResultsYounger age at transplantation was associated with improved cognitive function (p=0.001), receptive and expressive language (p=0.004 and p=0.01), and adaptive behavior (p=0.03).InterpretationEarly age at transplantation is a strong predictor of cognitive, language, and adaptive behavior outcomes. Children younger than 9 months at the time of transplant showed normal cognitive development. Our results demonstrate that early diagnosis is necessary for optimal outcomes and support the need for newborn screening since most patients are not identified at this young age. ANN NEUROL 2014. © 2014 American Neurological Association
    Annals of Neurology 11/2014; 76(5). DOI:10.1002/ana.24246 · 11.91 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Mucopolysaccharidosis type I (MPS I) is a progressive lysosomal storage disease. Impaired degradation of glycosaminoglycans triggers complex pathophysiological cascades, leading to a heterogeneous multisystem disorder. Two treatment modalities are available: enzyme replacement therapy and hematopoietic stem cell transplantation. Despite these treatments, a significant residual disease burden is observed in most patients.Areas covered: This review provides an overview of the currently known pathophysiological mechanisms underlying disease manifestations in MPS I. Additionally, the clinical presentation of the wide phenotypic spectrum is discussed, as well as methods for the phenotypical classification of patients and available treatment options, with a special focus on the treatment of residual disease.Expert opinion: Residual disease is currently the most pressing issue in MPS I, often requiring multiple surgical interventions. Several strategies are being explored to decrease the residual disease burden including modifications to the current treatment regimens and new therapeutic approaches. Optimal management of disease manifestations requires international collaboration and a standardized follow-up to collect essential clinical data.
    02/2015; DOI:10.1517/21678707.2015.1016908